StatOrigin open statistical archive
Industries Indicators Regions Rankings Reports Compare Sources

Clinical trial country use share vs First-in-class drug approvals in China

In 2023, clinical trial country use share in China was 15%; first-in-class drug approvals was 40.

Change the pair

Compare different indicators

The series

Over time

China, spaced by time in 2023 . Different units, drawn on separate scales and clipped to the years both series publish — earlier history stays on each indicator's own page. Read the values, not the heights.

Clinical trial country use share

Unit: % · 1 observation

Line chart
Clinical trial country use shareClinical trial country use share. 1 observations from 2023 to 2023, ranging from 15% to 15%. % 0 3 6 9 12 15 31 Dec 2 Jan 2023 15%
Clinical trial country use shareClinical trial country use share. 1 observations from 2023 to 2023, ranging from 15% to 15%. % 0 5 10 15 31 Dec 2 Jan 2023 15%
Clinical trial country use shareClinical trial country use share. 1 observations from 2023 to 2023, ranging from 15% to 15%. % 0 5 10 15 31 Dec 2 Jan 2023 15%
View the underlying data
Clinical trial country use share
Period Type Value
2023 Actual 15%
Source: IQVIA · CC BY 4.0 · Full series

First-in-class drug approvals

Unit: count · 1 observation

Line chart
First-in-class drug approvalsFirst-in-class drug approvals. 1 observations from 2023 to 2023, ranging from 40 to 40. 0 10 20 30 40 31 Dec 2 Jan 2023 40
First-in-class drug approvalsFirst-in-class drug approvals. 1 observations from 2023 to 2023, ranging from 40 to 40. 0 10 20 30 40 31 Dec 2 Jan 2023 40
First-in-class drug approvalsFirst-in-class drug approvals. 1 observations from 2023 to 2023, ranging from 40 to 40. 0 10 20 30 40 31 Dec 2 Jan 2023 40
View the underlying data
First-in-class drug approvals
Period Type Value
2023 Actual 40
Source: NMPA · CC BY 4.0 · Full series

Shared periods

Side by side

Only one period is published for both series in China. Comparing anything else would mean comparing different years.

Period Clinical trial country use share First-in-class drug approvals
2023 15% 40

Provenance

Where these numbers come from

Clinical trial country use share

Percentage of total clinical trial country uses accounted for by a given region.

3 observations in China · source organisations: IQVIA

First-in-class drug approvals

Number of approved therapeutic drugs featuring a novel biological mechanism of action.

4 observations in China · source organisations: NMPA, NHSA

Data published under CC BY 4.0. Series A as JSON · Series B as JSON

Keep exploring

Related

The two series

Go further